BRCA1 and triple-negative breast carcinoma: We explored the hypothesis that triple-negative breast cancers with high HRD scores (cohort A) or any solid tumor with germline or somatic mutations in HRD-associated genes other than BRCA1 and BRCA2 (cohort B) could be used to select patients for talazoparib monotherapy in the Talazoparib Beyond BRCA phase II clinical trial.